Low PTEN Levels and PIK3CA Mutations Predict Resistance to Neoadjuvant Lapatinib and Trastuzumab without Chemotherapy in Patients with HER2 Over-Expressing Breast Cancer

PURPOSE: Aberrant activation of the PI3K pathway has been implicated in resistance to HER2 targeted therapy, but results of clinical trials are confounded by the co-administration of chemotherapy. We investigated the effect of perturbations of this pathway in breast cancers from patients treated wit...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Breast Cancer Res Treat
Autors principals: Rimawi, Mothaffar F., De Angelis, Carmine, Contreras, Alejandro, Pareja, Fresia, Geyer, Felipe C., Burke, Kathleen A., Herrera, Sabrina, Wang, Tao, Mayer, Ingrid A, Forero, Andres, Nanda, Rita, Goetz, Matthew P., Chang, Jenny C., Krop, Ian E., Wolff, Antonio C., Pavlick, Anne C., Fuqua, Suzanne A. W., Gutierrez, Carolina, Hilsenbeck, Susan G., Li, Marilyn M., Weigelt, Britta, Reis-Filho, Jorge S., Osborne, C. Kent, Schiff, Rachel
Format: Artigo
Idioma:Inglês
Publicat: 2017
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5821069/
https://ncbi.nlm.nih.gov/pubmed/29110152
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-017-4533-9
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars